Figure 1.

Establishment and primary treatment of parental PDX. (A) Illustration of workflow. Patient-derived tumor cell lines were propagated subcutaneously in athymic nude mice, then engrafted intracranially and treated with radiation (RT) and temozolomide (TMZ). Post-therapy PDX were serially passaged subcutaneously through 3 mice. After therapy and propagation, derivative PDX cells were tested for in vitro and in vivo therapy resistance and underwent whole-exome sequencing (WES). (B) Bioluminescence (BLI) monitoring of intracranial engraftment of parental GBM6 with vehicle treatment versus treatment with RT monotherapy, and versus TMZ monotherapy. (C) BLI monitoring of intracranial engraftment of parental GBM6 with vehicle treatment versus treatment with one concomitant cycle of RT and TMZ, and versus treatment with a concomitant cycle of RT and TMZ followed by two additional cycles of TMZ at the indicated time points (n = 5 mice total for (B,C)).